FDA Aligns With Oncolytics on Registrational Path for Colorectal Cancer Drug
ONCY is trading near its 52-week low of $0.73 (14% above the low) on light trading volume (0.4× avg).
Summary
Oncolytics received FDA written feedback aligning on a potential pivotal Part B expansion of its REO 033 colorectal cancer trial. This is a major regulatory milestone for pelareorep in second-line RAS-mutant MSS colorectal cancer, a large indication with high unmet need. The alignment follows rapid site activation in the trial and comes amid going concern doubts and a Nasdaq delisting notice, making this a critical positive catalyst for the company's survival. The FDA's agreement on the registrational path significantly de-risks the program and could attract partnership or financing interest. Investors should watch for the formal initiation of Part B and any subsequent financing announcements.
At the time of this announcement, ONCY was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $104.9M. The 52-week trading range was $0.73 to $1.51. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.